Applications are open for the second Advancing BioBusiness Award.

Applications for the Advancing BioBusiness Award, being piloted by drug company Merck Sharpe & Dohme (MSD) and not-for-profit networking organisation Advance, close on 25 January, 2007.

Australia, take a bow -- you've proved you can compete in the global clinical trials market. But let's not get too complacent, writes Graeme Blackman.

Antisense Therapeutics (ASX:ANP) has produced positive results from a 'proof-of-concept' study of its second generation antisense drug ATL1101 to suppress the insulin-like growth factor-1 receptor (IGF-1R), which is under development as a cream for the topical treatment of the skin disorder psoriasis.

Pharmaceutical manufacturing and drug development company Institute of Drug Technology Australia (ASX:IDT) has reported an operating profit after tax of AUD$4.5 million for the year ended June 30, representing an increase of 5 per cent over the previous year.

Unlisted Brisbane biotech Xenome has initiated a Phase I clinical trial of its lead candidate for treating neuropathic pain, Xen2174.

Melbourne-based drug development and manufacturing company Institute of Drug Technology Australia (ASX:IDT) has posted record revenues of AUD$25.8 million for the 2002-2003 financial year.